|Table of Contents|

Safety and clinical efficacy of PD-1 inhibitor combined with targeted drugs in the treatment of advanced primary liver cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
875-880
Research Field:
Publishing date:

Info

Title:
Safety and clinical efficacy of PD-1 inhibitor combined with targeted drugs in the treatment of advanced primary liver cancer
Author(s):
YAN Xiangyong1; LI Jun1; NIU Xiaojuan1; LIN Caijuan1; SONG Shuzheng1; DANG Zheng2
1.Department of Integrative Medicine;2.Department of Hepatobiliary Surgery,the 940th Hospital of PLA Joint Logistics Support Force,Gansu Lanzhou 730050,China.
Keywords:
advanced primary liver cancer; PD-1 inhibitor; targeted drugs; safety; effectiveness
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.05.017
Abstract:
Objective：To explore the safety and efficacy of PD-1 inhibitor combined with targeted drugs in the treatment of advanced primary liver cancer.Methods:A total of 70 patients with advanced primary liver cancer admitted to our hospital from 2019 to 2020 were selected as the research subjects and divided into two groups,which were treated with single drug PD-1 inhibitor(single drug treatment group) and pD-1 inhibitor combined with targeted drug therapy(combined drug treatment group).The relevant medical records and efficacy and safety data of the two groups were retrospectively analyzed.Results:Safety comparison showed that the probability of AE events in the monotherapy group was skin and subcutaneous tissue diseases(17.14%),abnormal liver function(25.71%),hematological toxicity(31.42%),systemic symptoms(8.57%),gastrointestinal tract(17.14%),respiratory system,chest and mediastinal diseases(11.43%).Metabolic and nutritional diseases accounted for 20.00%,kidney and urinary system diseases for 5.71%,endocrine system diseases for 5.71%.The incidence of AE events in the combination group was 22.85% for skin and subcutaneous tissue diseases,28.57% for abnormal liver function,25.71% for hematological toxicity,11.43% for systemic symptoms,20.00% for gastrointestinal tract,14.29% for respiratory system,chest and mediastinal diseases,and 17.14% for metabolic and nutritional diseases.Kidney and urinary system diseases accounted for 8.57%,endocrine system diseases accounted for 2.86%(P＞0.05).Efficacy comparison showed that the complete response rate,partial response rate,disease stability rate and disease progression rate in monotherapy group were 8.57%,31.43%,48.57% and 11.43% respectively.In the combined treatment group,the complete response rate was 14.29%,partial response rate was 54.29%,disease stability rate was 25.71%,and disease progression rate was 5.71%,indicating significant differences and comparability(P＜0.05).The combination group was more effective against the disease.The level of lymohocyte was higher than that of single drug group(P＜0.05).Conclusion:PD-1 inhibitor combined with targeted drug therapy can achieve better clinical effect than single drug PD-1 inhibitor therapy for patients with advanced primary liver cancer,ensuring sufficient safety for patients.

References:

[1] 徐细明.肝癌的免疫治疗进展［J］.中国临床医学,2019,12(4):347-353. XU XM.Progress in immunotherapy of hepatocellular carcinoma ［J］.Chinese Journal of New Clinical Medicine,2019,12(4):347-353.
[2] 殷鹏,胡朝全.免疫检查点抑制剂治疗晚期肝细胞癌的进展［J］.中国普外基础与临床杂志,2020,12(14):16-17. YIN P,HU ZQ.Progress of immune checkpoint inhibitors in treatment of advanced hepatocellular carcinoma［J］.Chinese Journal of Bases and Clinics in General Surgery,2020,12(14):16-17.
[3] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南［J］.中国实用外科杂志,2022,42(3):241-271. Bureau of Medical Administration,National Health Commission of the People's Republic of China.Standardization for diagnosis and treatment of hepatocellular carcinoma ［J］.Chinese Journal of Practical Surgery,2022,42(3):241-271.
[4] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[5]张中林,张潇,李锟,等.吲哚菁绿荧光显像引导在腹腔镜肝中叶切除术中的应用［J］.腹部外科，2019,32(01):13-16. ZHANG ZL,ZHANG X,LI K,et al.Application of indocyanine green fluorescence imaging in laparoscopic hepatic middle lobe resection［J］.Journal of Abdominal Surgery,2019,32(01):13-16.
[6]蔡秀军,郑强,蒋广宜.肝癌外科治疗的现状和展望［J］.中华外科杂志,2019,57(07):494-499. CAI XJ,ZHENG Q,JIANG GY.Current status and prospect of surgical treatment for hepatocellular carcinoma［J］.Chinese Journal of Surgery,2019,57(07):494-499.
[7]张雨康,牛丽娟,王勇.射频消融在原发性肝癌临床治疗中的研究现状与进展［J］.癌症进展,2017,15(01):15-17. ZHANG YK,NIU LJ,WANG Y.Ablation techniques consensus development conferences as topic treatment for hepatocellular carcinoma［J］.Oncology Progress,2017,15(01):15-17.
[8]吴林鸿,谭辉,李照,等.原发性肝癌射频消融治疗与手术切除的疗效差异［J］.内蒙古医学杂志,2019,51(10):1174-1176. WU LH,TAN H,LI Z,et al.To analyze the difference between radiofrequency ablation and surgical resection for primary liver cancer［J］.Inner Mongolia Medical Journal,2019,51(10):1174-1176.
[9]周旭林,满沐苒,刘清华.放疗在肝癌治疗中应用的研究进展［J］.现代肿瘤医学,2019,27(14):2608-2611. ZHOU XL,MAN MR,LIU QH.Research progress of radiotherapy in the treatment of hepatocellular carcinoma［J］.Modern Oncology,2019,27(14):2608-2611.
[10]邓柑雀,黄广优,蒙以良,等.原发性肝癌介入联合三维适形放疗疗效观察［J］.基层医学论坛,2013,17(04):486-487. DENG GQ,HUANG GY,MENG YL,et al.Three-dimensional conformal radiation therapy for primary liver cancer［J］.The Medical Forum,2013,17(04):486-487.
[11]陈磊,陈诗,郑传胜.肝癌放射治疗研究进展［J］.介入放射学杂志,2020,29(06):631-635. CHEN L,CHEN S,ZHENG CS.Research progress in radiotherapy for liver cancers［J］.Journal of Interventional Radiology,2020,29(06):631-635.
[12]佘明金.卡瑞利珠单抗治疗恶性肿瘤的临床研究进展［J］.癌症进展,2020,18(9):865-869. SHE MJ.Progress on clinical research of camrelizumab in cancer treatment［J］.Oncology Progress,2020,18(9):865-869.
[13]秦叔逵,马军,李进,等.卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识［J］.临床肿瘤学杂志,2020,25(9):840-848. QIN SK,MA J,LI J,et al.Expert consensus on the clinical diagnosis and treatment of camrelizumab induced reactive cutaneous capillary endothelial proliferation［J］.Chinese Clinical Oncology,2020,25(9):840-848.
[14]滕颖,丁晓燕,李文东,等.程序性细胞死亡受体1抑制剂联合仑伐替尼治疗晚期原发性肝癌的效果及不良反应［J］.临床肝胆病杂志,2021,37(3):606-610． TENG Y,DING XY,LI WD,et al.Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events［J］.Journal of Clinical Hepatology,2021,37(3):606-610.
[15]邹添添,覃伟,朱迎,等.肝癌免疫微环境与免疫治疗:研究进展与发展趋势［J］.中国普通外科杂志,2020,29(7):785-797. ZOU TT,QIN W,ZHU Y,et al.Immune microenvironment and immunotherapy in hepatocellular carcinoma:research progress and development directions［J］.Chinese Journal of General Surgery,2020,29(7):785-797.
[16]何其宽,叶志宇,陈晓岗.肝癌免疫微环境及免疫治疗最新进展［J］.肝胆胰外科杂志,2019,31(12):705-709. HE QK,YE ZY,CHEN XG.Immunomicroenvironment and immunotherapy of hepatocellular carcinoma［J］.Journal of Hepatopancreatobiliary Surgery,2019,31(12):705-709.
[17] 杨荷,陈晓琦,王新亭,等.扶正消瘤颗粒联合卡瑞利珠单抗与阿帕替尼治疗晚期原发性肝癌临床观察［J］.中西医结合肝病杂志,2021,31(8):679-682. YANG H,CHEN XQ,WANG XT,et al.Observation on fuzhengxiaoliu glonules combincd carrelizumab and apatinib mesylate in the treatment of advanced primary liver cancer under the intervention of traditional Chinese medicine［J］.Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases,2021,31(8):679-682.
[18]许怡,郭云,黄颖,等.乙型病毒性肝炎并原发性肝癌患者外周血中T淋巴细胞的表达研究［J］.现代中西医结合杂志,2020,29(36):4010-4014. XU Y,GUO Y,HUANG Y,et al.Study on the expression of T lymphocytes in peripheral blood of patients with hepatitis B and primary liver cancer［J］.Modern Journal of Integrated Traditional Chinese and Western Medicine,2020,29(36):4010-4014.

Memo

Memo:
National Natural Science Foundation of China（No.82173738）;国家自然科学基金面上项目（编号：82173738）;甘肃省自然科学基金（编号：20JR10RA001）;甘肃省兰州市科技计划项目（编号：2018-3-60）
Last Update: 2023-01-31